AlphaValue Corporate Services
COVERAGE ABOUT US CONTACT FR
This research has been commissioned and paid for by the company and does therefore not constitute an inducement caught by the prohibition under MiFID II

Crossject

CR 		Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things are getting going...hopefully in FY25
Target
Upside 283%
Price (€) 1.89
Target Price (€) 7.22
Market Cap (€M) 84.7
Perf. 1W: -4.26%
Perf. 1M: 7.77%
Perf. 3M: -8.89%
Perf Ytd: -15.0%
10 day relative perf. to stoxx600: 6.68%
20 day relative perf. to stoxx600: 6.89%
EPS change18/08/2021 19:35
Download

Change in EPS2021 : € 0.18 vs 0.18-0.32%
2022 : € 0.91 vs 0.91-0.32%

We have only integrated the detailed numbers for FY20, which translate into a slightly lower EPS. However, the change is not meaningful given the still very low level of results of the company before its products reach the market.
Updates
.